SpringWorks Therapeutics Inc

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in applying a precision medicine approach to acquiring, developing and commercializing medicines. It focuses on developing drugs for underserved patient populations suffering from devastating rare diseases and cancer. Its pipeline include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SpringWorks reports robust Q1 revenue, poised for patient-centric growth

SpringWorks Therapeutics demonstrated strong financial performance and market acceptance for OGSIVEO in Q1 2024.
The company's focus on patient-centric care and pipeline advancement positions them well for future growth and innovation.
While facing challenges in market competition and regulatory landscape, SpringWorks has opportunities for expansion and diversification.

SpringWorks reports robust Q2 earnings, focuses on expanding treatments

SpringWorks Therapeutics delivered strong financial performance in Q2 2024, driven by $40.2 million in net product revenue for OGSIVEO.
The company's focus on expanding OGSIVEO reach, advancing mirdametinib, and developing its emerging portfolio underscores its commitment to innovation.
While facing challenges such as rising operating expenses, SpringWorks remains well-positioned with a healthy cash reserve to pursue growth opportunities.
Strategically navigating challenges and capitalizing on opportunities will be crucial for SpringWorks to sustain its momentum and drive future success.

SpringWorks Therapeutics reports robust Q3 performance and eyes growth opportunities

SpringWorks Therapeutics demonstrates strong financial performance, a solid balance sheet, and positive market reception for their products. While regulatory hurdles exist, opportunities for growth through new approvals and expanded patient populations present promising prospects for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Springworks Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the application of a medicine approach to acquiring, developing, and commercializing medicines. Its pipeline includes Nirogacestat, Mirdametinib, Brimarafenib, SW-682, and EGFR Inhibitor. The company was founded in August 2017 and is headquartered in Stamford, CT.

STAMFORD, Conn., Nov. 23, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference, taking place virtually on Tuesday, November 30, 2021, at 3:30 pm ET.

SpringWorks Therapeutics to Participate in the 4th Annual Evercore ISI HealthCONx Conference

– Announced Advancement into Randomized Phase 2 Expansion and Addition of New Sub-studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refractory Multiple Myeloma –

SpringWorks Therapeutics Reports Third Quarter 2021 Financial Results and Recent Business Highlights

-- Based on Encouraging Preliminary Data Observed with the First Dose Exploration Cohort (0.95 mg/kg BLENREP Q3W + Nirogacestat) a Randomized Phase 2 Cohort Expansion to Compare Against 2.5 mg/kg Q3W BLENREP Monotherapy Has Been Initiated -- -- Two New Sub-Studies of BLENREP + Nirogacestat Combined with Standard-of-Care Therapies Now Planned --

SpringWorks Therapeutics Announces the Initiation of an Expanded Phase 2 Cohort and Addition of New Sub-Studies to Existing Clinical Collaboration with GlaxoSmithKline Evaluating Nirogacestat in Combination with BLENREP in Patients with Relapsed or Refrac

– SpringWorks to Utilize Pioneering Computational Modeling Approaches Developed by Yibing Shan, Ph.D., Previously Founding Member of DE Shaw Research and Leading Computational Structural Biologist –

SpringWorks Therapeutics to Collaborate with Ab Magnitude on Target Identification and Discovery of Next-Generation Targeted Oncology Therapeutics

- Portfolio is Currently in Lead Optimization and Includes Several Novel Approaches for Targeting Mutant EGFR that are Designed to Address Both De Novo Oncogenic Drivers and Emerging Resistance Mutations -

SpringWorks Therapeutics to Collaborate with Leading Academic Institutions to Advance Portfolio of Next-Generation Mutation-Selective EGFR Inhibitors

STAMFORD, Conn., Sept. 07, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference. A webcast of the company presentation will be available on-demand starting Monday, September 13, 2021 at 7:00 am ET.

SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

-- Research to be Led by Constantine Mitsiades, M.D., Ph.D., at Dana-Farber Cancer Institute -- -- Research to be Led by Constantine Mitsiades, M.D., Ph.D., at Dana-Farber Cancer Institute --

SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma

– Entered into Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA and Dosed First Patients in Three Phase 1 Clinical Trials Evaluating Nirogacestat in Combination with BCMA Therapies Across Modalities in Patients with Relapsed or Refractory Multiple Myeloma –

SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Platform Study to Evaluate Mirdametinib as a Combination Therapy with Fulvestrant in Patients with ER+ Metastatic Breast Cancer and as a Monotherapy in Patients with Advanced Solid Tumors Harboring Activating Mutations in MEK1 or MEK2 Platform Study to Evaluate Mirdametinib as a Combination Therapy with Fulvestrant in Patients with ER+ Metastatic Breast Cancer and as a Monotherapy in Patients with Advanced Solid Tumors Harboring Activating Mutations in MEK1 or MEK2

SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations

STAMFORD, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,066,358 (the ‘358 patent), directed to mirdametinib, the Company's product candidate in development for several oncology indications, including as a monotherapy for patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The ‘358 patent, assigned to Warner-Lambert Company LLC (a subsidiary of Pfizer), expires in 2041. The ‘358 patent is a composition of matter patent that covers the polymorphic form of mirdametinib that is currently in clinical development. SpringWorks has exclusive rights to the ‘358 patent pursuant to an existing worldwide license with Pfizer.

SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041

Annovis Bio

Brooklyn ImmunoTherapeutics

Citius Pharmaceuticals

Jazz Pharmaceuticals

Mind Medicine MindMed

Cassava Sciences Inc

Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.

7 Top-Rated Pharmaceutical Companies to Invest In for July

Precision Biosciences

Precision BioSciences Inc (NASDAQ: DTIL) and SpringWorks Therapeutics Inc (NASDAQ: SWTX) have dosed the first patient in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A.  In the study, Precision's investigational allogeneic BCMA-targeted CAR T cell therapy will be combined with nirogacestat, SpringWorks' investigational gamma-secretase inhibitor in relapsed/refractory multiple myeloma.

Precision BioSciences Moves Higher After Commencing Dosing In PBCAR269A Combination Arm Of Multiple Myeloma Trial

DURHAM, N.C. & STAMFORD, Conn.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that the first patient has been dosed in the combinat

Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma

SpringWorks Therapeutics Inc (NASDAQ: SWTX) announced an update on the previously reported interim data from the first 20 adult patients enrolled in Phase 2b ReNeu trial evaluating mirdametinib for NF1-associated plexiform neurofibromas (NF1-PN), Data were presented at the 2021 Children's Tumor Foundation NF Conference.

SpringWorks Therapeutics Reveals Updated Interim Mirdametinib Data In Rare Genetic Disorder

STAMFORD, Conn., June 16, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported the initiation of a Phase 1/2 clinical trial to evaluate mirdametinib, an investigational MEK inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). The study is sponsored by St. Jude Children's Research Hospital. More information on the trial can be found on www.clinicaltrials.gov under the identifier NCT04923126.

SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma

Additional Follow-up of First 20 Adult Patients Enrolled Continues to Show Encouraging Efficacy and Tolerability of Mirdametinib in Patients with NF1-PN Additional Follow-up of First 20 Adult Patients Enrolled Continues to Show Encouraging Efficacy and Tolerability of Mirdametinib in Patients with NF1-PN

SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children's Tumor Foundation NF Conference

Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities Continued Execution on Strategy to Advance Nirogacestat as a BCMA Potentiator Across Modalities

SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma

STAMFORD, Conn., June 01, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8th at 3:00PM ET.

SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference

STAMFORD, Conn., May 14, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a Fireside Chat at the Cowen 2nd Annual Oncology Innovation Summit on Friday, May 21st at 10:00AM ET.

SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit

Allakos Inc

Horizon Pharma

ImmunityBio

I-Mab

SAGE Therapeutics

As the market gets back to normal, it's a great time to explore the pharma stocks that got lost in the vaccine frenzy of the past year. The post 7 of the Best Pharma Stocks to Buy Now appeared first on InvestorPlace.

7 of the Best Pharma Stocks to Buy Now

STAMFORD, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that Mike Burgess, M.B.Ch.B., Ph.D. has been appointed Head of Research and Development (R&D). Dr. Burgess is a physician-scientist with clinical experience in pediatrics and pediatric oncology and over 20 years of pharmaceutical industry R&D leadership experience across several therapeutic areas, including oncology. Dr. Burgess will lead the R&D organization as the company continues to advance its diversified targeted oncology pipeline and to expand its portfolio with additional oncology programs. He succeeds Stephen Squinto, Ph.D., who served as Acting Head of R&D since the company's launch in 2017. Dr. Squinto will continue to serve on the SpringWorks Board of Directors.

SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development

SpringWorks Therapeutics Inc (NASDAQ: SWTX) has entered into an exclusive worldwide license agreement with Katholieke Universiteit Leuven (KU Leuven) and the Flanders Institute for Biotechnology (VIB) for the in-license of small molecule inhibitors of the TEA domain (TEAD) family of transcription factors for biomarker-defined solid tumors driven by aberrant Hippo pathway signaling. The licensed portfolio includes advanced lead compounds and multiple backup compounds from diverse chemical series.

SpringWorks In-Licenses TEAD Inhibitor Portfolio For Solid Tumor Settings

– Reported Interim Data from Phase 2b ReNeu Trial of Mirdametinib in NF1-PN Demonstrating Encouraging Clinical Activity and Tolerability in the First 20 Adult Patients Enrolled –

SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

- TEAD Inhibition Represents an Emerging Approach for Addressing Multiple Biomarker-Defined Cancers Characterized by Aberrant Hippo Pathway Signaling, which is Genetically Altered in up to 10% of Cancers -

SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio

SWTX has a late-stage pipeline with potential approvals next year. There's a lot of cash reserve.

News for SpringWorks Therapeutics Inc Stock (SWTX)